NeOnc Technologies Holdings, Inc. filed an 8-K on November 17, 2026, disclosing investor presentation materials that include an update on the NEO100 Phase 2a clinical study, with the earliest reported event dated November 16, 2026.

Key Highlights

  • Additional response confirmed: The company disclosed an additional response in the NEO100 Phase 2a study, bringing the total to 3 responses out of 24 patients.
  • Objective response rate increased: The objective response rate rose from 8.3% to 12.5%, as assessed using RANO 2.0 criteria, according to the filing.
  • Presentation venue: Management intends to use the presentation, possibly with modifications, in one or more meetings with current and potential investors.
  • Forward-looking statements present: The presentation contains forward-looking statements; the filing directs readers to Page 3 of the presentation for a discussion of risks and uncertainties.
  • Emerging growth company: The registrant identified itself as an emerging growth company under applicable SEC rules.

NEO100 Phase 2a Clinical Update Disclosed by NeOnc Technologies

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), headquartered in Calabasas, California, filed a Current Report on Form 8-K reporting under Item 7.01 (Regulation FD Disclosure). According to the filing, the company furnished an investor presentation dated November 16, 2026, that management plans to use, "possibly with modifications, in one or more meetings from time to time with current and potential investors."

The central clinical disclosure, found on slides 16 and 17 of the presentation, concerns the NEO100 Phase 2a study. The company reported that it "has confirmed an additional response in the NEO100 Phase 2a study, bringing the total number of responses to 3 of 24 patients and increasing the objective response rate from 8.3% to 12.5%, as assessed using RANO 2.0 criteria." The filing does not identify the specific tumor type or patient population beyond this description.

The filing notes that the presentation "contains forward-looking statements" and directs readers to Page 3 of the presentation for the relevant discussion of risks and uncertainties. The company stated it "specifically disclaims any obligation" to update the presentation to reflect future events. The filing also states that the information furnished under Item 7.01, including the attached Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. The report was signed by Amir Heshmatpour, Chief Executive Officer, President and Executive Chairman.

What Was Disclosed

NeOnc Technologies Holdings, Inc. furnished an investor presentation under Regulation FD reporting a confirmed additional response in its NEO100 Phase 2a study, raising the total to 3 of 24 patients and the objective response rate to 12.5% using RANO 2.0 criteria.